tiprankstipranks
The Fly

Ideaya Biosciences reports Q3 EPS (46c), consensus (49c)

Ideaya Biosciences reports Q3 EPS (46c), consensus (49c)

Reports Q3 revenue $8.04M, consensus $7.32M. “We have advanced a diverse clinical pipeline of precision medicine oncology therapies targeting biomarker-defined solid tumor populations. Our innovative clinical pipeline has four potential first-in-class clinical programs, including darovasertib (PKC) in a Phase 2/3 potential registrational trial, IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1, and GSK101/IDE705 (Pol Theta Helicase) in Phase 1. We also selected a Werner Helicase Development Candidate in collaboration with GSK, for which an IND submission is planned for 2024. These programs represent five potential first-in-class programs, further validating our robust drug discovery platform and enhancing our industry leadership in precision medicine oncology,” said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on IDYA:

Questions or Comments about the article? Write to editor@tipranks.com